FDAnews
www.fdanews.com/articles/143226-ganetespib-synergizes-with-taxanes-in-multiple-nsclc-models-synta-says

Ganetespib Synergizes with Taxanes in Multiple NSCLC Models, Synta Says

January 16, 2012
Ganetespib, a non-ansamycin inhibitor of Hsp90, enhances the activity of the microtubule targeting docetaxel, paclitaxel, and vincristine in multiple non-small cell lung cancer (NSCLC) xenograft models, according to an article published in the journal Investigational New Drugs. Ganetespib currently is being studied in combination with docetaxel in a Phase IIb/III clinical trial (GALAXY) in NSCLC.
MarketWatch